Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform

Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle® Platform

First regulatory T cell program to onboard to the Cell Shuttle, bringing automated cGMP manufacturing and QC infrastructure to Treg cell therapies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced a collaboration to automate manufacturing of lead SonomaBio® program, SBT-77-7101, on the Cellares Cell Shuttle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713633810/en/

SBT-77-7101 is an autologous CAR-Treg cell therapy in Phase 1 clinical development for poly-refractory rheumatoid arthritis (RA), the most challenging RA patients, who have exhausted all available treatment options. The program is the first Treg cell therapy to onboard to the Cell Shuttle, extending Cellares’ automated manufacturing platform into a modality that demands precise handling and analytical control to preserve Treg identity and function.